Cell Signaling Technology

Product Pathways - Growth Factors/Cytokines

Human His6Fas Ligand/TNFSF6 (hHis6FasL) #5452

his tag   TNFSF6   Tumor necrosis factor ligand superfamily member 6  

No. Size Price
5452SC 10 µg ( With Carrier ) ¥2,644.00 现货查询 购买询价 防伪查询
5452SF 10 µg ( Carrier Free ) ¥2,644.00 现货查询 购买询价 防伪查询
5452 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype

Species cross-reactivity is determined by western blot.

Applications Key:

Source / Purification

Recombinant humanHis6 FasL (hHis6FasL) Pro134-Leu281 (Accession #NP_000630) was expressed in human 293 cells at Cell Signaling Technology.

CST公司生产的人重组蛋白His6FasL (hHis6FasL) Pro134-Leu281 (Accession #NP_000630)是从人的293细胞表达而来。

Molecular Characterization

Recombinant N-terminally His6-tagged hFasL has a calculated MW of 19,834. DTT-reduced and non-reduced protein migrate as 31-36 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation.



>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hHis6FasL. All lots are greater than 98% pure.

6 μg 还原 (+) 和 非还原的(-) 重组hHis6FasL通过SDS-PAGE检测,纯度大于98%,所有批次的纯度均高于98%。


The bioactivity of hHis6FasL was determined in a Jurkat cell viability assay. The ED50 of each lot is between 1-5 ng/ml.

hHis6FasL的生物活性是通过Jurkat细胞生存能力的实验来确定的。每个批次的ED50在1-5 ng/ml之间。



The viability of Jurkat cells treated with increasing amounts of hHis6FasL in the presence of 10 µg/ml anti-His antibody was assessed. After 24 hour treatment with hHis6FasL, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.在10 µg/ml抗His抗体存在下,用递增浓度的hHis6FasL培养Jurkat并观察其生存能力的实验。用hHis6FasL培养细胞24小时后与四唑盐孵育并测定 OD450-OD650 数值。

Sandwich ELISA

Sandwich ELISA

Treatment of Jurkat cells with hHis6FasL induces casapase-3 cleavage as detected by PathScan® Cleaved Caspase-3 (Asp175) Sandwich ELISA Kit #7190.用PathScan® Cleaved Caspase-3 (Asp175) Sandwich ELISA Kit #7190测定用 hHis6FasL 诱导Jurkat细胞casapase-3 的剪切。

Western Blotting

Western Blotting

Western blot analysis of extracts from Jurkat cells, untreated or treated with hHis6FasL for 3 hours, using Cleaved PARP (Asp214) Antibody (Human Specific) #9541 (upper) or PARP Antibody #9542 (lower).Western免疫印迹。用Cleaved PARP (Asp214) Antibody (Human Specific) #9541(上图)和PARP Antibody #9542 (下图) 研究未经处理的和经hHis6FasL处理3小时的Jurkat细胞的细胞提取液。

Coomassie Gel

Coomassie Gel

The purity of recombinant hHis6FasL was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hHis6FasL and staining overnight with Coomassie Blue.重组 hHis6FasL蛋白的纯度通过SDS-PAGE 来确定。6 µg 经还原(+)和未经过还原(-) 的重组hHis6FasL蛋白跑SDS胶并用考马斯亮蓝染色过夜。


Less than 0.01 ng endotoxin/1 μg hHis6FasL.

每微克hFasL内毒素含量小于0.01 ng。


With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hHis6FasL. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

有载体:每微克hHis6FasL蛋白溶解在包含20 μg BSA的PBS(pH 7.2)的溶液中,并通过 0.22 μm 滤膜冻干。

无载体:每微克hHis6FasL蛋白溶解在PBS(pH 7.2)溶液,并通过 0.22 μm 滤膜冻干。


FasL is a member of the TNF-superfamily family of proteins and is expressed primarily on the cell surface of activated T and NK cells (1). FasL regulates the immune response through its ability to induce apoptosis. The immunoregulatory role of FasL is underscored by lymphoadenopathy associated with FasL or Fas knockout mice and the fraction of autoimmune lympho-proliferative syndrome (ALPS) patients that have mutations in the FasL receptor, Fas (1). FasL is a membrane protein that can be cleaved into a soluble trimeric form by metalloproteinases (1,2). The soluble form of FasL retains the ability to bind to Fas, however, its ability to induce apoptosis is diminished (2). The ligation of Fas by FasL leads to the assembly of death-inducing signaling complex (DISC) and the recruitment and activation of caspase-8/caspase-10 (1,3). Active caspase-8/caspase-10 subsequently activates the “effector” caspases caspase-3 and caspase-7, and cleavage of BID (1,3).

FasL是TNF超家族蛋白中的一员,并且主要在激活的T细胞和NK细胞的表面表达(1)。FasL通过其诱导凋亡的能力来调控免疫反应。FasL的免疫调控能力在淋巴结病中被低估,主要表现在FasL或者Fas敲除小鼠会发生淋巴结病 ,FasL受体突变会导致人自体免疫淋巴增生综合症(1)。FasL是一个膜蛋白,能够被金属蛋白酶剪切形成可溶的三聚体形式(1,2)。可溶性的FasL仍然具有结合Fas的能力,然而其诱导凋亡的能力会消失(2)。Fas被FasL结合后,导致死亡诱导信号复合体(DISC)形成,并招募和激活caspase-8/caspase-10 (1,3)。激活的caspase-8/caspase-10随后激活“效应因子”caspases(caspase-3 和caspase-7)并剪切BID (1,3)。

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

PathScan is a trademark of Cell Signaling Technology, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0


我要参与评论 :